| Literature DB >> 32183489 |
Beata Rzepka-Migut1, Justyna Paprocka2.
Abstract
Melatonin plays an important role in regulating the sleep-wake cycle and adaptation to environmental changes. Concentration measurements in bioliquids such as serum/plasma, saliva and urine are widely used to assess peripheral rhythm. The aim of the study was to compare methods and conditions of determinations carried out with the identification of factors potentially affecting the measurements obtained. We have identified a group of modifiable and unmodifiable factors that facilitate data interpretation. Knowledge of modifiers allows you to carefully plan the test protocol and then compare the results. There is no one universal sampling standard, because the choice of method and biofluid depends on the purpose of the study and the research group.Entities:
Keywords: DLMO; Dim light melatonin onset; body fluids; drugs; measurement methods; melatonin
Year: 2020 PMID: 32183489 PMCID: PMC7142625 DOI: 10.3390/ijerph17061916
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Chemical structure of N-acetyl-methoxytryptamine.
Figure 2Chemical structure of 6-sulfatoxymelatonin.
Figure 3Chemical structure of hydroxymelatonin.
Effects of drugs on melatonin secretion.
| References | Drug | Effects on Melatonin Secretion |
|---|---|---|
| Cowen PJ et al., 1985 [ | beta-blockers (propranolol, atenolol) | lower mean melatonin concentration |
| Brismar K et al., 1987 [ | beta-blockers | decreased night-time melatonin secretion |
| Rommel T et al., 1994 [ | beta-blockers (propranolol, ridazolol) | decreased melatonin secretion |
| Stoschitzky K et al., 1999 [ | beta-blockers (atenolol) | decreased melatonin secretion |
| Takaesu Y et al., 2015 [ | beta-blockers | no significant differences |
| Muñóz-Hoyos A et al., 2000 [ | α2 adrenergic agonist (clonidine) | decreased melatonin secretion |
| Murphy PJ et al., 1996 [ | nonsteroidal anti-inflammatory drug (NSAIDs) | decreased nightly melatonin secretion |
| Monteleone P et al., 1989 [ | GABAergic drug | decreased night-time melatonin secretion |
| Monteleone P et al., 1997 [ | GABAergic drug | decreased melatonin secretion |
| Gupta M et al., 2006 [ | carbamazepine+melatonin | melatonin levels in patients receiving CBZ+MLT were higher than those of the VPA+MLT recipient group |
| Praninskiene R et al., 2012 [ | antiepilepticdrugs | no significant differences |
| Dabak O et al., 2015 [ | antiepilepticdrugs | no significant differences |
| McIntyre IM et al., 1988 [ | benzodiazepines | decreased night-time melatonin secretion |
| Copinschi G et al., 1990 [ | short-acting benzodiazepine (triazolam) | no significant differences |
| Claustrat B et al., 2005 [ | monoamine oxidase inhibitors (MAO) | increased melatonin secretion |
| Claustrat B et al., 2005 [ | tricyclic antidepressants | increased melatonin secretion |
| Skene DJ et al., 1994 [ | the specific serotonin uptake inhibitor (fluvoxamine) | increased nocturnal plasma melatonin concentrations |
| Skene DJ et al., 1994 [ | the noradrenaline uptake inhibitor (desipramine) | increased evening plasma melatonin concentrations |
Effects of sexual hormones on melatonin secretion.
| References | Participants | Effects on Melatonin Secretion |
|---|---|---|
| Kostoglou-Athanassiou I et al., 1998 [ |
women on oral contraceptives women not on oral contraceptives | overall melatonin secretion was augmented |
| Cook MR et al., 2000 [ |
women who took hormone replacement therapy women who did not take hormone replacement therapy | no effect observed |
| Burgess HJ et al., 2008 [ |
females who used hormonal birth control therapy females who did not use hormonal birth control therapy males | longer duration time of melatonin secretion |
| Gunn PJ et al., 2016 [ |
women on oral contraceptives males | significantly elevated plasma melatonin levels in women, no significant differences in aMT6 levels |
Sampling guidelines for melatonin according to Benloucif S et al. 2011.
| Material | Determined Substances | Sampling Periods | Lighting | Body Posture | Basis for Evaluating the Circadian Rhythm Phase |
|---|---|---|---|---|---|
| urine | aMT6s | every 2 to 8 h for 24 to 48 h or the first morning urine sample | not applicable | restriction of motor activity and change of body position before and during sampling | the timing of the acrophase |
| saliva | melatonin | every 30 to 60 min starting at least one hour before and throughout the expected increase in melatonin levels | <30 lux | DLMO | |
| blood | melatonin | frequent sampling with a catheter inserted at least 2 h before the expected increase in melatonin levels | <30 lux | DLMO |